Gordon Rustin
East and North Herts NHS Trust
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gordon Rustin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:03 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT02055690 · PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian CancerThe Christie NHS Foundation Trust · terminated · Ovarian Neoplasms, Neoplasms, Ovarian, Ovarian Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:03 UTC. The ranking covers the 200 most relevant of 87 PubMed records, and a shared surname and initials can bring in a namesake. All 87 on PubMed
- Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.N Engl J Med · 20121,491 citationsRCR 36.1
- 1,161 citationsRCR 32.0
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.Lancet Oncol · 2015683 citationsRCR 21.5
- Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).J Clin Oncol · 2004535 citationsRCR 12.7
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).Br J Cancer · 1992420 citationsRCR 12.4
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.Lancet · 2010412 citationsRCR 10.1
- 358 citationsRCR 10.2
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.J Clin Oncol · 1996326 citationsRCR 10.0
- Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.Lancet · 2005314 citationsRCR 7.3
- Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.J Clin Oncol · 2003272 citationsRCR 6.1